Quick Answer
AVENUE THERAPEUTICS, INC. reported Operating Income Loss of -$3.08 million for the year ending 2025.
- AVENUE THERAPEUTICS, INC. showed an increase of +72.7% in Operating Income Loss from 2024 to 2025.
- This data is from AVENUE THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), AVENUE THERAPEUTICS, INC.'s Operating Income Loss has grown by 36.3%.
- Historical annual values: Fiscal year 2025: -$3.08 million | Fiscal year 2024: -$11.28 million | Fiscal year 2023: -$14.54 million | Fiscal year 2022: -$8.04 million | Fiscal year 2021: -$3.74 million | Fiscal year 2020: -$5.21 million | Fiscal year 2019: -$26.27 million | Fiscal year 2018: -$21.82 million | Fiscal year 2017: -$11.42 million | Fiscal year 2016: -$2.38 million | Fiscal year 2015: -$4.84 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: